Maryland Senate Bill 435

---

Sponsorship: Partisan Bill (Republican 1)
Status: Introduced on January 30 2026 - 25% progression, died in chamber
Action: 2026-04-13 - Motion Laid Over (Senator Ready) Adopted
Text: Latest bill text (Introduced) [PDF]

Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.

Public Health - Medetomidine and Xylazine Consumer Protection Act

Sen. William Folden [R]

Date	Chamber	Action
2026-04-13	Senate	Motion Laid Over (Senator Ready) Adopted
2026-04-13	Senate	Favorable with Amendments {983727/1
2026-04-13	Senate	Favorable with Amendments Report by Finance
2026-02-03	Senate	Hearing 2/11 at 2:00 p.m.
2026-01-30	Senate	First Reading Finance

HB417 (Crossfiled) 2026-04-13 - Motion Special Order until Next Session (Senator Love) Adopted
SB875 (Carry Over) 2025-03-04 - Hearing 3/11 at 1:00 p.m.

Chapter	Article	Section	Citation Type	Statute Text
Health - General	21-2G	01	(n/a)	See Bill Text
Health - General	21-2G	2	(n/a)	See Bill Text
Health - General	21-2G	3	(n/a)	See Bill Text
Health - General	8	6A-01	(n/a)	See Bill Text

Type	Source
Summary	https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/SB0435?ys=2026RS
Text	https://mgaleg.maryland.gov/2026RS/bills/sb/sb0435f.pdf
Amendment	https://mgaleg.maryland.gov/2026RS/amds/bil_0005/sb0435_98372701.pdf
Supplement	https://mgaleg.maryland.gov/2026RS/votes_comm/sb0435_fin.pdf